Clinical Pharmacokinetics

, Volume 1, Issue 4, pp 264–279 | Cite as

Propranolol Disposition in Chronic Liver Disease: A Physiological Approach

  • R. A. Branch
  • D. G. Shand
Article

Summary

The pharmacokinetics of propranolol can be quantitatively explained on a physiological basis from a knowledge of the effects of four biological determinants: (1) the activity of the drug metabolising enzymes (intrinsic clearance); (2) hepatic blood flow; (3) drug binding, and (4) the anatomical arrangement of the hepatic circulation. Disturbances of all these determinants can occur in chronic liver disease and result in predictable changes in propranolol disposition. These changes, as well as those occurring with other drugs in chronic liver disease, may be explained by ‘intact hepatocyte theory’ which postulates that the major pathophysiological change occuring in compensated chronic liver disease is a reduction in relatively normally perfused and functioning cell mass with the development of intrahepatic portosystemic vascular shunts.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander, J.F.; Lischner, M.W. and Galambos, J.T.: Natural history of alcoholic hepatitis II The long term prognosis. American Journal of Gastroenterology 56: 515–525 (1971).PubMedGoogle Scholar
  2. Andreason, P.B.; Ranek, L.; Statland, B.E. and Tygstrup, R.: Clearance of antipyrine dependence of quantitative liver function. European Journal of Clinical Investigation 4: 129–134 (1974).Google Scholar
  3. Andreason, P.B. and Vesel, E.S.: Comparison of plasma levels of antipyrine, tolbutamide and warfarin after oral and intravenous administration. Clinical Pharmacology and Therapeutics 16: 1059–1065 (1974).Google Scholar
  4. Baker, K.J.: Binding of sulphobromophthalein (BSP) sodium and indocyanine green (ICG) by plasma a-1-lipoproteins. Proceedings of the Society of Medicine and Biology 122: 957–958 (1966).Google Scholar
  5. Bond, P.A.: Metabolism of propranolol (Inderal); a potent, specific β-adrenergic receptor blocking agent. Nature 213: 721–723 (1967).PubMedCrossRefGoogle Scholar
  6. Bradley, W.E.; Ingelfinger, J.F.; Bradley, G.P. and Curry, J.J.: The estimation of hepatic blood flow in man. Journal of Clinical Investigation 24: 890–897 (1945).CrossRefGoogle Scholar
  7. Bradley, S.E.; Ingelfinger, F.J. and Bradley, G.P.: Hepatic circulation in cirrhosis of the liver. Circulation 5: 419–429 (1952).PubMedCrossRefGoogle Scholar
  8. Branch, R.A.; Herbert, C.M. and Read, A.E.: Determinants of serum antipyrine half-lives in patients with liver disease. Gut 14: 569–573 (1973).PubMedCrossRefGoogle Scholar
  9. Branch, R.A.; James, J.A. and Read, A.E.: The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic liver disease. Clinical Pharmacology and Therapeutics (In press, 1976a).Google Scholar
  10. Branch, R.A.; James, J. and Read, A.E.: A study of factors influencing drug disposition in chronic liver disease using the model drug (+)-propranolol. British Journal of Clinical Pharmacology (In press, 1976b).Google Scholar
  11. Branch, R.A.; Nies, A.S. and Shand, D.G.: Disposition of propranolol VIII. General implications of the effects of liver blood flow on elimination from the perfused rat liver. Drug Metabolism and Disposition 1: 687–690 (1973).PubMedGoogle Scholar
  12. Branch, R.A.; Shand, D.G. and Nies, A.S.: Increase in hepatic blood flow and d-propranolol clearance by glucagon in the monkey. Journal of Pharmacology Experimental Therapeutics 187: 581–587 (1973).Google Scholar
  13. Branch, R.A.; Shand, D.G.; Wilkinson, G.R. and Nies, A.S.: Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Journal of Clinical Investigation 53: 1101–1107 (1974).PubMedCrossRefGoogle Scholar
  14. Breckenridge, A.M.; Buranapong, P.; Dollery, C.T.; George, C.F.; Macerlean, D. and Orme, M.L.E.: Hepatic clearance of propranolol in dogs. British Journal of Pharmacology 48: 336P (1973).PubMedGoogle Scholar
  15. Brodie, B.B. and Axelrod, J.: Fate of antipyrine in man. Journal of Pharmacology and Therapeutics 98: 97–104 (1950).Google Scholar
  16. Caesar, J.; Shaldon, S.; Chiandussi, L.; Guevana, L. and Sherlock, S.: The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clinical Science 21: 43–57 (1961).PubMedGoogle Scholar
  17. Cherrick, G.R.; Stein, S.W.; Leavy, C.M. and Davidson, C.S.: Indocyanine green: observations on its physical properties, plasma decay and hepatic extraction. Journal of Clinical Investigation 39: 592–600 (1960).PubMedCrossRefGoogle Scholar
  18. Cohn, J.N.; Khatri, I.M.; Groszmann, R.J. and Kotelanski, B.: Hepatic blood flow in alcoholic liver disease measured by an indicator dilution technique. American Journal of Medicine 53: 704–714 (1972).PubMedCrossRefGoogle Scholar
  19. Conn, H.O. and Lindenmuth, W.W.: Prophylactic portacaval anastomosis in cirrhotic patients with esophageal varices. A progress report of a continuing study. New England Journal of Medicine 272: 1255–1263 (1965).PubMedCrossRefGoogle Scholar
  20. Conn, H.O. and Lindenmuth, W.W.: Prophylactic portacaval anastomosis in cirrhotic patients with esophageal varices and ascites. Experimental design and preliminary results. American Journal of Surgery 117: 656–661 (1969).PubMedCrossRefGoogle Scholar
  21. Davies, D.S. and Prichard, B.N.C. (eds): Biological Effects of Drugs in Relation to their Plasma Concentration (Churchill Livingstone, Edinburgh; University Park Press Baltimore 1973).Google Scholar
  22. Evans, G.H.; Nies, A.S. and Shand, D.G.: The disposition of propranolol, III: Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. Journal of Pharmacology and Experimental Therapeutics 186: 114–122 (1973).PubMedGoogle Scholar
  23. Evans, G.H. and Shand, D.G.: Disposition of propranolol V: Drug accumulation and steady state concentrations during chronic oral administration in man. Clinical Pharmacology and Therapeutics 14: 487–493 (1973a).PubMedGoogle Scholar
  24. Evans, G.H. and Shand, D.G.: Disposition of propranolol VI: Independent drug concentration and half-life as a result of plasma drug binding in man. Clinical Pharmacology and Therapeutics 14: 494–506 (1973b).PubMedGoogle Scholar
  25. Forrest, J.A.H.; Finlayson, N.D.C.; Adjepon-Yomoah, K.K. and Prescott, L.F.: Antipyrine, lignocaine and paracetamol metabolism in chronic liver disease. Gut 67: 790 (1974).Google Scholar
  26. Gillette, J.R.: Factors affecting drug metabolism. Annals of the New York Academy of Science 179: 43–66 (1971).CrossRefGoogle Scholar
  27. Gram, L.F. and Qvero, K.F.: First pass metabolism of nortriptyline in man. Clinical Pharmacology and Therapeutics 18: 305–314 (1975).PubMedGoogle Scholar
  28. Gross, G. and Perrier, C.V.: Intrahepatic portasystemic shunting in cirrhotic patients. New England Journal of Medicine 293: 1046–1047 (1975).PubMedCrossRefGoogle Scholar
  29. Groszmann, R.; Kotelanski, B.; Cohn, J.N. and Khatri, I.M.: Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. American Journal of Medicine 53: 715–722 (1972).PubMedCrossRefGoogle Scholar
  30. Gugler, R.; Lain, P. and Azarnoff, D.L.: Effect of portacaval shunt on the disposition of drugs with and without first pass effect. Journal of Pharmacology and Experimental Therapeutics 195: 416–423 (1975).PubMedGoogle Scholar
  31. Jackson, F.C.; Derin, E.B.; Smith, A.G.; DaGradi, A.E. and Nadal, H.M.: A clinical investigation of the portacaval shunt II: Survival analysis of the prophylactic operation. American Journal of Surgery 115: 22–42 (1968).PubMedCrossRefGoogle Scholar
  32. Leevy, C.M.; Mendenhall, C.L.; Lesko, W. and Howard, M.M.: Estimation of hepatic blood flow with indocyanine green. Journal Clinical Investigation 41: 1169–1179 (1962).CrossRefGoogle Scholar
  33. Levy, G. (ed): Clinical Pharmacokinetics (American Pharmaceutical Association, Washington 1974).Google Scholar
  34. Levy, G. and Yacobi, A.: Effect of plasma protein binding on elimination of warfarin. Journal of Pharmaceutical Sciences 63: 805–806 (1974).PubMedCrossRefGoogle Scholar
  35. May, B.; Helmstaedt, D.; Bustgens, L. and McLean, A.: A relation between cytochrome P450 in liver biopsies and drug metabolism in patients with liver disease and in morphine addiction. Clinical Science 46: 11PGoogle Scholar
  36. Mawer, G.E.; Miller, N.E. and Turnburg, L.A.: Metabolism of amylobarbitone in patients with chronic liver disease. British Journal of Pharmacology 44: 549–560 (1972).PubMedCrossRefGoogle Scholar
  37. Mistilis, S.P. and Blackburn, C.R.B.: The treatment of active chronic hepatitis with 6 mercaptopurine and azothiaprine. Australasian Annals of Medicine 16: 305–311 (1967).PubMedGoogle Scholar
  38. Nies, A.S.; Evans, G.H. and Shand, D.G.: Regional hemodynamic effects of beta-adrenergic blockade with propranolol in the unanaesthetised primate. American Heart Journal 85: 97–102 (1973a).PubMedCrossRefGoogle Scholar
  39. Nies, A.S.; Evans, G.H. and Shand, D.G.: The hemodynamic effects of beta-adrenergic blockade on the flow dependent hepatic clearance of propranolol. Journal of Pharmacology and Experimental Therapeutics 184: 716–720 (1973b).PubMedGoogle Scholar
  40. Paterson, J.W.; Conolly, M.E.; Dollery, C.T.; Hayes, A. and Cooper, R.G.: The pharmacodynamics and metabolism of propranolol in man. Pharmacologia Clinica 2: 127–133 (1970).CrossRefGoogle Scholar
  41. Popper, H.; Elias, H. and Petty, D.E.: Vascular pattern of the cirrhotic liver. American Journal of Clinical Pathology 22: 717–729 (1952).PubMedGoogle Scholar
  42. Redeker, A.G.; Geller, H.M. and Reynolds, T.B.: Hepatic wedge pressure, blood flow, vascular resistance and oxygen consumption in cirrhosis before and after end-to-side portacaval shunt. Journal of Clinical Investigation 37: 606–618 (1958).PubMedCrossRefGoogle Scholar
  43. Reidenberg, M.M.: Renal function and drug action (Saunders, Philadelphia 1971).Google Scholar
  44. Resnick, R.H.; Chalmers, T.C.; Ishihara, A.M.; Garceau, A.J.; Callow, A.A.; Schimmel, E.M. and O’Hara, E.T.: The Boston Interhospital Liver Group: A controlled study of the prophylactic portacaval shunt. A final report. Annals of Internal Medicine 70: 675–688 (1969).PubMedGoogle Scholar
  45. Rowland, M.; Benet, L.Z. and Graham, G.G.: Clearance concepts in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1: 123–136 (1973).PubMedGoogle Scholar
  46. Schoene, G.; Fleischmann, R.A.; Remmer, H. and Oldershausen, H.F.: Determination of drug metabolizing enzymes in needle biopsies of human liver. European Journal of Clinical Pharmacology 4: 65–73 (1972).PubMedCrossRefGoogle Scholar
  47. Shand, D.G.; Evans, G.H. and Nies, A.S.: The almost complete hepatic extraction of propranolol during intravenous administration in the dog. Life Sciences 10: 1417–1421 (1971).CrossRefGoogle Scholar
  48. Shand, D.G.; Kornhauser, D.M. and Wilkinson, G.R.: Effects of route of administration and blood flow on hepatic drug elimination. Journal of Pharmacology and Experimental Therapeutics 195: 424–432 (1975).PubMedGoogle Scholar
  49. Shand, D.G. and Rangno, R.E.: The disposition of propranolol I. Elimination during oral absorbtion in man. Pharmacology 7: 159–168 (1972).PubMedCrossRefGoogle Scholar
  50. Shand, D.G.; Rangno, R.E. and Evans, G.H.: The disposition of propranolol II. Hepatic elimination in the rat. Pharmacology 8: 344–352 (1972).PubMedCrossRefGoogle Scholar
  51. Tygstrup, N. and Winkler, K.: Galactose blood clearance as a measure of hepatic blood flow. Clinical Science 17: 1–9 (1958).PubMedGoogle Scholar
  52. Walle, G. and Gaffney, T.E.: Propranolol metabolism in man and dog: Mass spectroscopic identification of six new metabolites. Journal of Pharmacology and Experimental Therapeutics 183: 83–92 (1972).Google Scholar
  53. Wheeler, H.O.; Craston, W.I. and Meltzer, J.I.: Hepatic uptake and biliary excretion of indocyanine green in the dog. Proceedings of the Society Experimental Biology (New York) 99: 11–16 (1958).Google Scholar
  54. Wilkinson, G.R.: Pharmacology of drug disposition: Hemodynamic Considerations. Annual Review of Pharmacology 15: 11–27 (1975).PubMedCrossRefGoogle Scholar
  55. Wilkinson, G.R. and Shand, D.G.: A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics 18: 377–390 (1975).PubMedGoogle Scholar

Copyright information

© ADIS Press 1976

Authors and Affiliations

  • R. A. Branch
    • 1
  • D. G. Shand
    • 1
  1. 1.Department of Medicine, Division of Clinical PharmacologyVanderbilt University School of MedicineNashvilleUSA

Personalised recommendations